Sponsored Content | Webinar | Radiation Therapy| August 28, 2018

WEBINAR: Treating Tumors that Move: The Promise and Practice of Real-time MR Image Guidance During Radiation Beam Delivery

Webinar is sponsored by ViewRay

Respiratory tumor motion often complicates the delivery of precision radiation treatment. Over the past two decades, radiotherapy researchers and clinicians have pursued several approaches to motion management. However, the approaches lacked continuous, high-quality soft tissue visualization linked to an automated beam-gating technology that would see when a tumor moved out of margin range and halt the delivery of radiation until it returned to a prescribed area (PTV).

With the introduction of magnetic resonance image (MRI) guidance and real-time image guidance during beam delivery, the ability to lessen or eliminate radiation dose to surrounding tissues and organs is achievable. Several studies have demonstrated: (1) the ability to reduce to a minimum the margin expansion necessary to account for motion error while reducing doses to nearby organs at risk, and (2) the ability to obtain duty cycles equal to or greater than those common to conventional gating.

In this webinar, two speakers will share their clinical experience with this MRI-Guided RT technology.

This webinar took place Sept. 20, 2018 — Register to view the archive version the webinar

 

Presenters:

John Ng, M.D.
Assistant Professor and Director of Medical Student Education in Radiation Oncology at Weill Cornell Medicine
[email protected]

John Ng is a Board Certified Radiation Oncologist and Assistant Professor of Radiation Oncology at Weill Cornell Medical College/New York Presbyterian Hospital. Dr. Ng attended Columbia University and then received an M.S. degree in Biophysics from Harvard University. He obtained his M.D. degree from Harvard Medical School, jointly with the Massachusetts Institute of Technology, as part of the Health Sciences and Technology (HST) program. Joining Weill Cornell Medical Center, he serves as attending physician for Breast Oncology and for Gastrointestinal Oncology. His current focus is on exploring emerging radiation technologies such as magnetic resonance imaging (MRI) guided radiation as a way of amplifying the host immune response to cancer cells.

 

Kathryn Mittauer, Ph.D., DABR
Staff Medical Physicist at University of Wisconsin-Madison
[email protected]

Mittauer is a staff medical physicist and researcher at the University of Wisconsin-Madison. She has specialized in clinical implementation and coverage of MR-guided radiotherapy with the ViewRay MRIdian system since 2015. She has a master’s degree in medical physics from the University of Kentucky and a doctorate in medical physics from the University of Florida. She completed her residency in medical physics at the University of Wisconsin-Madison. Her research efforts include using online adaptive MR-guided radiotherapy to assess normal tissue toxicities and dose escalation strategies.

 

About ViewRay

ViewRay Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purposely built to address specific challenges, including beam distortion, skin toxicity and other concerns that may potentially arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay Inc.

 

Register to view the archive version the webinar

Related Content

Sponsored Content | Videos | Radiation Therapy | January 18, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a look at product introductions for 2018 plus
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.